Kanaph Therapeutics Inc.

Research Kanaph Therapeutics Inc. (0082N0.KQ) on Bullrun: market cap KRW 135.64B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 135.64B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 135.64Bn/an/an/a

Dividend history

About Kanaph Therapeutics Inc.

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment;

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Pharmicell Co., Ltd. (005690.KS) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) Hyundai Bioscience Co., Ltd. (048410.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ) CTCBIO Inc. (060590.KQ)

Frequently asked questions

What is Kanaph Therapeutics Inc.'s market cap?

Kanaph Therapeutics Inc.'s market capitalization is KRW 135.64B.

What does Kanaph Therapeutics Inc. do?

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules.